RIPK1抑制剂SAR443820治疗肌萎缩侧索硬化的2期试验HIMALAYA
这项多中心、随机、双盲、安慰剂对照的2期试验评估了SAR443820在肌萎缩侧索硬化(ALS)患者中的安全性、耐受性和疗效。共随机分配305例患者(SAR443820组203例,安慰剂组102例),主要终点为24周时ALSFRS-R总分变化。结论认为SAR443820无临床获益,不支持进一步开发。
要点
- SAR443820未显著改善ALS患者24周ALSFRS-R评分。
- SAR443820组不良事件和治疗中断率高于安慰剂组。
- 肝酶升高是SAR443820组最常见的不良事件原因。
核心结论
- SAR443820在ALS患者中未显示临床获益,且与肝酶升高相关,不支持进一步临床开发。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照的2期试验,在13个国家63个中心进行,共随机分配305例ALS患者(SAR443820组203例,安慰剂组102例),按2:1比例分组,治疗24周。
主要发现
- 不良事件发生率:SAR443820组171/202(85%),安慰剂组80/102(78%);治疗中断率:SAR443820组28/202(14%),安慰剂组5/102(5%)。
- 双盲期内死亡9例(SAR443820组7/202(3%),安慰剂组2/102(2%)),均未归因于SAR443820。
临床怎么用
- 不推荐在ALS患者中使用SAR443820,因缺乏疗效且安全性风险增加。
局限性
- 试验被提前终止,可能影响结果的解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: RIPK1, a protein regulating inflammatory signalling and cell death, is implicated in amyotrophic lateral sclerosis (ALS) pathophysiology. SAR443820 is a selective, oral, CNS-penetrant, reversible RIPK1 inhibitor. We aimed to evaluate the safety, tolerability, and efficacy of SAR443820 in participants with ALS. METHODS: This multicentre, randomised, double-blind, placebo-controlled, phase 2 trial was conducted at 63 clinical sites in 13 countries (Belgium, Canada, China, France, Germany, Italy, Japan, the Netherlands, Poland, Spain, Sweden, the UK, and the USA). Adults (aged 18-80 years) with a diagnosis of possible ALS, clinically probable ALS, clinically probable laboratory-supported ALS, or clinically definite ALS, in accordance with the revised El Escorial World Federation of Neurology criteria, were randomly assigned (2:1) by use of a stratified block design (blocks of three) to receive either 20 mg SAR443820 orally twice per day or matching placebo in the 24-week double-blind period. Randomisation was done centrally using interactive response technology and stratified by geographical region of trial site, region of ALS onset, use of riluzole, use of edaravone, and use of the combination of sodium phenylbutyrate and taurursodiol. Participants, care providers, investigators, and outcomes assessors were masked to trial intervention. The primary outcome was a change in ALS Functional Rating Scale Revised (ALSFRS-R) total score from baseline to week 24 and was calculated for all participants who had an ALSFRS-R total score available at baseline and at week 24. Safety analyses included all randomly assigned participants receiving one dose or more of trial intervention. This trial is registered with ClinicalTrials.gov (NCT05237284) and was terminated early. FINDINGS: Between April 13, 2022, and July 17, 2023, 397 participants were screened and 305 randomly assigned to SAR443820 (n=203) or placebo (n=102); six were excluded from the primary analysis due to missing baseline ALSFRS-R values. Mean age was 56·9 years (SD 11·5); 183 (60%) participants were male and 122 (40%) were female. Least squares mean change in ALSFRS-R from baseline to week 24 was -6·73 (95% CI -7·48 to -5·98) for SAR443820 group (n=169) and -6·32 (-7·36 to -5·27) for placebo group (n=87). There was no statistically significant difference between the study groups (least squares mean difference -0·41 [95% CI -1·71 to 0·88]). Participants in the SAR443820 group had higher incidence of adverse events (171 [85%] of 202 vs placebo 80 [78%] of 102) and treatment discontinuations (28 [14%] of 202 vs placebo five [5%] of 102), with elevated hepatic enzymes being the most common cause. Nine deaths occurred in the double-blind period (seven [3%] of 202 in the SAR443820 group and two [2%] of 102 in the placebo group); none was attributed to SAR443820. INTERPRETATION: SAR443820 did not show clinical benefit and was associated with higher hepatic enzyme increase, indicating that further clinical development of SAR443820 in ALS is not warranted. FUNDING: Sanofi.
引用
- Cudkowicz ME, Shefner J, van den Berg LH, et al. Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2026. PMID: 42716044. doi:10.1016/S1474-4422(26)00277-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。